fresh funds

Houston biotech startup raises millions to battle pediatric cancer

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Trending News

Building Houston

 
 

"The Soccer Innovation Institute presents the ultimate opportunity to redefine the player and fan experience, and develop a lasting legacy for the long-term benefit of the FIFA World Cup." Photo via Paul Duron/Wikipedia

Houston is kicking up its 2026 FIFA World Cup bid by a notch or two with a new innovative initiative.

The Houston 2026 World Cup Bid Committee on October 14 committed to establishing the nonprofit Soccer Innovation Institute if Houston becomes a host city for the FIFA World Cup.

"The institute will rely on Houston's spirit of innovation to create a united community investment in building a legacy that goes well beyond the city," according to a news release announcing the potential formation of the nonprofit.

The soccer institute, made up of a network of experts and leaders from various global organizations, would conduct specialized think tanks and would support a series of community programs.

"As the energy capital of the world, the global leader in medicine, the universal headquarters for NASA, and the home to numerous sports tech companies, Houston has an abundance of resources that are unmatched by other cities," Houston billionaire John Arnold, chairman of the 2026 bid committee, says in a news release. "By bringing these organizations together under one umbrella, the Soccer Innovation Institute presents the ultimate opportunity to redefine the player and fan experience, and develop a lasting legacy for the long-term benefit of the FIFA World Cup."

Houston Mayor Sylvester Turner says the institute would align with the city's efforts to build a strong ecosystem for innovation, along with its passion for soccer.

"Houston is recognized as a leader in technology and innovation. We have many innovation hubs around the city that bring bright minds into collaborative spaces where the whole is greater than the sum of the parts," the mayor says.

Held every four years, the World Cup assembles national men's soccer teams from around the world in one of the most planet's most watched sporting events. The traditional 32-team tournament will expand to 48 teams in 2026. After 2026, the World Cup might be staged every two years.

Among those collaborating on the Houston 2026 bid are NRG, the Texas Medical Center, Shell, Chevron, the U.S. Soccer Foundation, the Council for Responsible Sport, the Houston Dynamo, the Houston Dash, the City of Houston, Harris County, and Houston First.

The FIFA World Cup 2026 will be played in 16 cities across the U.S., Mexico, and Canada. Houston and Dallas are among the 17 cities vying to become a U.S. host. A final decision is expected in the first half of 2022. If Houston is selected, it will host six World Cup games at NRG Stadium.

Between October 21 and November 1, World Cup delegates will visit eight cities in the running to be North American hosts: Houston, Dallas, Kansas City, Cincinnati, Denver, San Francisco, Seattle, and Monterrey, Mexico.

Trending News